Author

Laurie Domrzalski

Observed name: Domrzalski, Laurie

Institution: Ascendis Pharma (Denmark)

Observed institution: Ascendis Pharma (Denmark)

OpenAlex ID: A5107766331

12542 Results Of The Foresight Trial Support The Efficacy And Safety Of Once-weekly Lonapegsomatropin In Adults With Growth Hormone Deficiency (ghd)

2024 · Beverly Mk Biller, Aleksandra Gilis-Januszewska, et al. · Journal of the Endocrine Society · 2

Long-term Safety and Efficacy of Once-Weekly Lonapegsomatropin in Adults With Growth Hormone Deficiency: Results From a 52-Week Open-Label Extension Trial

2026 · Beverly M.K. Biller, Aleksandra Gilis-Januszewska, et al. · Endocrine Practice

Results of the foresiGHt trial support the efficacy and safety of once-weekly lonapegsomatropin in adults with growth hormone deficiency (GHD)

2025 · Aleksandra Gilis-Januszewska, Beverly M.K. Biller, et al. · Endocrine Abstracts

Biller et al. JCEM Supplementary Materials

2025 · Biller, Beverly, Gilis-Januszewska, Aleksandra, et al. · Figshare

Works count: 4

Citation count: 2

H-index: 1

I10-index: